Drug Discovery

Pharmaxis is targeting the following inflammatory and fibrotic diseases using its amine oxidase platform:

  • Non-alcoholic steatohepatitis (NASH)
  • Liver fibrosis
  • Pulmonary fibrosis
  • Kidney fibrosis
  • Cardiac fibrosis
  • COPD
  • Diabetic retinopathy
  • Cancers with fibrotic components including myelofibrosis and pancreatic cancer
  • Inflammatory bowel diseases

Pharmaxis aims to improve success rates, minimise drug discovery costs and speed up development timelines by focusing on targets that have been independently validated in diseases with limited treatment options and where its amine oxidase platform can be utilised. 

Drug discovery schematic

Amine oxidase drug development programs currently being investigated by Pharmaxis include:

  • Selective LOXL2 inhibitor for NASH, lung, liver and kidney fibrosis - successfully completed phase 1 trials in the fourth quarter of 2018
  • LOX inhibitor: scarring (commenced preclinical development), cancer (commenced phase 1 clinical trials in the February 2019)
  • SSAO/MPO combination for inflammation (preclinical development)